VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:VX1 - US92532F1003 - Common Stock
389.95 EUR
+1.85 (+0.48%)
Taking everything into account, VX1 scores 7 out of 10 in our fundamental rating. VX1 was compared to 82 industry peers in the Biotechnology industry. VX1 gets an excellent profitability rating and is at the same time showing great financial health properties. VX1 is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, VX1 could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year VX1 was profitable.
VX1 had a positive operating cash flow in the past year.
Of the past 5 years VX1 4 years were profitable.
VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of VX1 (14.78%) is better than 87.80% of its industry peers.
VX1's Return On Equity of 21.22% is amongst the best of the industry. VX1 outperforms 90.24% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.66%, VX1 belongs to the top of the industry, outperforming 91.46% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for VX1 is significantly above the industry average of 12.14%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROIC | 15.67% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
1.3 Margins
VX1 has a Profit Margin of 31.35%. This is amongst the best in the industry. VX1 outperforms 86.59% of its industry peers.
Looking at the Operating Margin, with a value of 38.70%, VX1 belongs to the top of the industry, outperforming 92.68% of the companies in the same industry.
In the last couple of years the Operating Margin of VX1 has grown nicely.
VX1 has a better Gross Margin (86.28%) than 78.05% of its industry peers.
VX1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
VX1 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
VX1 has less shares outstanding than it did 1 year ago.
VX1 has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, VX1 has an improved debt to assets ratio.
2.2 Solvency
VX1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.78
WACC8.82%
2.3 Liquidity
A Current Ratio of 2.36 indicates that VX1 has no problem at all paying its short term obligations.
VX1 has a Current ratio of 2.36. This is comparable to the rest of the industry: VX1 outperforms 48.78% of its industry peers.
VX1 has a Quick Ratio of 2.00. This is a normal value and indicates that VX1 is financially healthy and should not expect problems in meeting its short term obligations.
VX1 has a Quick ratio of 2.00. This is comparable to the rest of the industry: VX1 outperforms 46.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 3303.92%, which is quite impressive.
VX1 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.14% yearly.
Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 10.33% in the last year.
VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
3.2 Future
Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 150.35% on average per year.
VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.70% yearly.
EPS Next Y6342.88%
EPS Next 2Y738.5%
EPS Next 3Y328.69%
EPS Next 5Y150.35%
Revenue Next Year10.14%
Revenue Next 2Y9.44%
Revenue Next 3Y9.38%
Revenue Next 5Y9.7%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 26.47, VX1 can be considered very expensive at the moment.
76.83% of the companies in the same industry are more expensive than VX1, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.59, VX1 is valued at the same level.
With a Price/Forward Earnings ratio of 22.54, VX1 is valued on the expensive side.
Based on the Price/Forward Earnings ratio, VX1 is valued cheaper than 81.71% of the companies in the same industry.
VX1 is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.03, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.47 | ||
| Fwd PE | 22.54 |
4.2 Price Multiples
71.95% of the companies in the same industry are more expensive than VX1, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, VX1 is valued a bit cheaper than 79.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.94 | ||
| EV/EBITDA | 23.29 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of VX1 may justify a higher PE ratio.
A more expensive valuation may be justified as VX1's earnings are expected to grow with 328.69% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y738.5%
EPS Next 3Y328.69%
5. Dividend
5.1 Amount
VX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:VX1 (12/23/2025, 7:00:00 PM)
389.95
+1.85 (+0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.5%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap98.94B
Revenue(TTM)11.72B
Net Income(TTM)3.68B
Analysts76.41
Price Target430.15 (10.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)1.63%
PT rev (3m)3.31%
EPS NQ rev (1m)0.56%
EPS NQ rev (3m)2.37%
EPS NY rev (1m)1.66%
EPS NY rev (3m)1.36%
Revenue NQ rev (1m)0.25%
Revenue NQ rev (3m)-0.83%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.47 | ||
| Fwd PE | 22.54 | ||
| P/S | 9.95 | ||
| P/FCF | 34.94 | ||
| P/OCF | 31.36 | ||
| P/B | 6.73 | ||
| P/tB | 7.38 | ||
| EV/EBITDA | 23.29 |
EPS(TTM)14.73
EY3.78%
EPS(NY)17.3
Fwd EY4.44%
FCF(TTM)11.16
FCFY2.86%
OCF(TTM)12.43
OCFY3.19%
SpS39.2
BVpS57.92
TBVpS52.84
PEG (NY)0
PEG (5Y)N/A
Graham Number138.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.78% | ||
| ROE | 21.22% | ||
| ROCE | 22.25% | ||
| ROIC | 15.67% | ||
| ROICexc | 22.65% | ||
| ROICexgc | 25.38% | ||
| OM | 38.7% | ||
| PM (TTM) | 31.35% | ||
| GM | 86.28% | ||
| FCFM | 28.47% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 189.83% | ||
| Cap/Sales | 3.25% | ||
| Interest Coverage | 374.91 | ||
| Cash Conversion | 78.49% | ||
| Profit Quality | 90.81% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2 | ||
| Altman-Z | N/A |
F-Score7
WACC8.82%
ROIC/WACC1.78
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3303.92%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%9.59%
EPS Next Y6342.88%
EPS Next 2Y738.5%
EPS Next 3Y328.69%
EPS Next 5Y150.35%
Revenue 1Y (TTM)10.33%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%10.99%
Revenue Next Year10.14%
Revenue Next 2Y9.44%
Revenue Next 3Y9.38%
Revenue Next 5Y9.7%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year811.13%
EBIT Next 3Y127.98%
EBIT Next 5Y68.84%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.
What is the valuation status of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.
What is the profitability of VX1 stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 26.47 and the Price/Book (PB) ratio is 6.73.
What is the financial health of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 7 / 10.